VTx 002 - VectorY Therapeutics
Alternative Names: VTx-002 - VectorY TherapeuticsLatest Information Update: 19 Jun 2024
At a glance
- Originator VectorY
- Class Antibodies; Gene therapies; Immunoglobulin Fv fragments
- Mechanism of Action TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 13 Nov 2023 VectorY Therapeutics plans clinical trial in Amyotrophic lateral sclerosis (Parenteral)
- 01 Jun 2022 Preclinical pharmacodynamic data in Amyotrophic lateral sclerosis released by VectorY
- 18 May 2022 VTx 002 - VectorY Therapeutics is available for licensing as of 18 May 2022. https://www.vectorytx.com/careers